These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sublingual vaccines based on wild-type recombinant allergens.
    Author: Van Overtvelt L, Razafindratsita A, St-Lu N, Didierlaurent A, Batard T, Lombardi V, Martin E, Moingeon P.
    Journal: Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785.
    Abstract:
    Sublingual immunotherapy (SLIT) represents a non invasive alternative to subcutaneous immunotherapy in order to treat type I allergies. Vaccines based on recombinant allergens expressed in a native (i.e. wild-type) configuration, formulated with ad hoc adjuvants designed to target Langerhans cells in the sublingual mucosa should allow to induce allergen-specific regulatory T cells. In this context, we have developed animal and human preclinical models to test the capacity of candidate vaccines to modulate selectively allergen-specific T helper lymphocyte polarization following sublingual vaccination.
    [Abstract] [Full Text] [Related] [New Search]